Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. cardioprotectmi

CardioProtectMI SIGNED

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CardioProtectMI project word cloud

Explore the words cloud of the CardioProtectMI project. It provides you a very rough idea of what is the project "CardioProtectMI" about.

therapeutics    stages    improvement    chronic    survival    therapies    market    consequence    12    trials    emerged    million    reperfusion    mi    treatments    10    supporting    humans    tissues    reveal    biotechnology    damage    innovation    recommend    cardio    blood    failed    mortality    animal    protective    clinical    peptide    aps    disease    ihd    resother    drug    myocardial    acute    strategic    utmost    company    efficacy    ischaemic    drugs    injury    date    effect    rate    itself    flow    safety    models    incidence    readiness    ensuing    procedure    52    smei    death    serious    business    congestive    opportunity    alone    guidelines    class    validation    stopping    14    stakeholders    inflammatory    generation    heart    mitigate    strategies    therapeutic    first    cell    later    engage    resolution    anti    medium    reported    human    decreases    positioning    deaths    candidate    plan    prepare    severe    therapy    6    causing    pharma    tissue    prove    inflammation    restoration    infarction    400    provider   

Project "CardioProtectMI" data sheet

The following table provides information about the project.

Coordinator		 RESOTHER PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: KOBENHAVN
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESOTHER PHARMA APS DK (KOBENHAVN) coordinator 50˙000.00

Map

 Project objective

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOPROTECTMI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOPROTECTMI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More